| Figures/TablesFigures/Tables | ReferencesReferencesml version=""1.0"" encoding=""UTF-8""?>
Background
Mesenchy
mal ste
m cells (MSCs) i
mprove postische
mic
myocardial function in part through their secretion of growth factors such as vascular endothelial growth factor (VEGF). Pretreating MSCs with various cytokines or s
mall
molecules can i
mprove VEGF secretion and MSC-
mediated cardioprotection. However, whether 1 cytokine can potentiate the effect of another cytokine in MSC pretreat
ment to achieve a synergistic effect on VEGF production and cardioprotection is poorly studied.
Methods
MSCs were treated with interleukin (IL)-1¦Â and/or transforming growth factor (TGF)-¦Â1 for 24 hours before experiments. VEGF production was determined by enzyme-linked immunosorbent assay. Isolated hearts from adult male Sprague-Dawley rats were subjected to 15 minutes of equilibration, 25 minutes of ischemia, and 40 minutes reperfusion. Hearts (m>nm> = 5-7 per group) were randomly infused with vehicle, untreated MSCs, or MSCs pretreated with IL-1¦Â and/or TGF-¦Â1. Specific inhibitors were used to delineate the roles of p38 mitogen-activated protein kinase (MAPK) and SMAD3 in IL-1¦Â- and TGF-¦Â1-mediated stimulation of MSCs.
Results
MSCs cotreated with IL-1¦Â and TGF-¦Â1 exhibited synergistically increased VEGF secretion, and they greatly improved postischemic myocardial functional recovery. Ablation of p38 MAPK and SMAD3 activation with specific inhibitors negated both IL-1¦Â- and TGF-¦Â1-mediated VEGF production in MSCs and the ability of these pretreated MSCs to improve myocardial recovery after ischemia.
Conclusion
Pretreating MSCs with 2 cytokines may be useful to fully realize the potential of cell-based therapies for ischemic tissues.